USP sets the benchmark for medical product quality. Our work strengthens quality assurance systems across the global medicines supply chain, building upon our 200-year history in advancing access to quality-assured medicines.
With world-class quality control labs in India and Ghana as well as in the US, we are advancing the science of quality control and leading the use of risk-based testing and mitigation strategies to meet global standards for quality and excellence.
USP-India is strategically located in the epicenter of global generics manufacturing. Our close collaboration with hundreds of generic manufacturers provides unparalleled knowledge and insights of the global generics supply chain that helps identify risks during times of crises such as the COVID-19 pandemic.
Risk-based approaches help optimize resources for post-marketing surveillance. USP has developed a number of implementation resources to help regulators, particularly those in low- and middle-income countries, detect poor-quality medicines.
New USP program builds confidence and trust by confirming the ability of a laboratory to conduct testing and analysis to ensure reliable testing results and providing a measure of the overall proficiency of the laboratory.
USP–Ghana works with partners to develop skills to deliver quality assured medicines to people who need them most.
Practical strategies to help detect substandard and falsified vaccines
Faced with poor-quality medicines, health leaders around the world need more data to make strategic decisions about investments. USP’s Quality Institute is developing research addressing evidence gaps, ultimately strengthening understanding of the value of quality medicines.
